Naltrexone delayed release - Aardvark Therapeutics
Alternative Names: ARD-301; DBR-LDN; delayed-release naltrexone hydrochloride; SP 104Latest Information Update: 28 Mar 2024
At a glance
- Originator Aardvark Therapeutics
- Developer Aardvark Therapeutics; Sorrento Therapeutics
- Class Analgesics; Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Fibromyalgia; Pain
- Discontinued Post acute COVID 19 syndrome
Most Recent Events
- 20 Mar 2024 Sorrento Therapeutics plans a phase-II trial for fibromyalgia and Pain in 2024 (PO)
- 04 Feb 2023 Discontinued - Phase-I for Post-acute-COVID-19-syndrome (In volunteers) in New Zealand (PO) (Aardvark Therapeutics pipeline, February 2023) (Sorrento Therapeutics pipeline, February 2023)
- 11 May 2022 Adverse events data from a phase I trial in healthy volunteers released by Scilex